Long-term efficacy of allergen immunotherapy: What do we expect?

Immunotherapy

Volumn 5, Issue 2, 2013, Pages 131-133

  Frati, Franco ^a   Dell'Albani, Ilaria ^a   Incorvaia, Cristoforo ^b  

^a Medical and Scientific Department   (Italy)

^b ICP Hospital   (Italy)

Author keywords

allergen specific immunotherapy; duration of treatment; long term efficacy

Indexed keywords

BUDESONIDE; HOUSE DUST ALLERGEN; PLACEBO;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FOLLOW UP; FORCED EXPIRATORY VOLUME; GRASS POLLEN; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHINOCONJUNCTIVITIS; SENSITIZATION; TREATMENT DURATION;

ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DUST; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874044584     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.154     Document Type: Article

References (14)

1. Incorvaia C, Frati F. One century of allergen-specific immunotherapy for respiratory allergy. Immunotherapy 3, 629-635 (2011).
2. Larchè M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6, 761-771 (2006).
3. Passalacqua G. Specific immunotherapy: beyond the clinical scores. Ann. Allergy Asthma Immunol. 107, 401-406 (2011).
4. Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann. Allergy Asthma Immunol. 98, 416-426 (2007).
5. Golden DB. Discontinuing venom immunotherapy. Curr. Opin Allergy Clin. Immunol. 1, 353-356 (2001).
6. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: A 10-year prospective study. Clin. Exp. Allergy 33, 206-210 (2003).
7. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J. Allergy Clin. Immunol. 129, 717-725 (2012).
8. Stelmach I, Sobocinska A, Majak P, Smejda C, Jerzynska J, Stelmach W. Comparison of the long-term efficacy of 3-and 5-year house dust mite allergen immunotherapy. Ann. Allergy Asthma Immunol. 109, 274-278 (2012).
9. Cox L, Nelson H, Lockey E et al. Allergen immunotherapy: A practice parameter third update. J. Allergy Clin. Immunol. 127, S1-S55 (2011).
10. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: A review. Curr. Opin Allergy Clin. Immunol. 8, 585-589 (2008).
11. Golden DB, Moffitt J, Nicklas RA et al. Stinging insect hypersensitivity: A practice parameter update 2011. J. Allergy Clin. Immunol. 127, 852-854 (2011).
12. Greisner WA, Settipane RJ, Settipane GA. Natural history of hay fever: A 23-year followup of college students. Allergy Asthma Proc. 19, 271-275 (1998).
13. Howarth P, Malling HJ, Molimard M, Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 67, 321-327 (2012).
14. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 319-325 (2006).